Paris-based biotechnology company Orakl Oncology has raised $34 million in an oversubscribed Series A financing round, bringing its total funding to $50 million. The investment will support the expansion of its artificial intelligence platform, which combines patient-derived tumor models with clinical data to predict cancer treatment responses and clinical trial outcomes.
Founded in 2023 as a spin-out of France’s Gustave Roussy cancer campus, Orakl develops virtual cancer patient cohorts by integrating laboratory-grown tumor organoids, multi-omic profiling, and longitudinal clinical records. Unlike approaches relying exclusively on retrospective genomic datasets, its platform incorporates experimental drug-response data to model how different tumor subtypes respond to therapeutic compounds.
The company reports that its predictive engine has achieved 90% accuracy in forecasting cancer clinical trial outcomes, including prospective predictions aligned with recent pancreatic cancer trial results. Beyond estimating clinical endpoints such as progression-free survival, the technology identifies biomarkers associated with treatment response and investigates mechanisms underlying drug sensitivity and resistance.
Just over a year after its commercial launch, Orakl has established a commercial pipeline involving 18 of the world's 20 largest pharmaceutical companies. Initial engagements are progressing into multi-year collaborations, including work evaluating oncology assets for Sanofi.
The new financing will support four areas of expansion. Orakl plans to strengthen its AI research capabilities in Paris, increase experimental laboratory data generation fivefold, and extend its disease coverage beyond colorectal and pancreatic cancers to include non-small cell lung cancer and gastric cancer.
The company will also establish commercial and scientific teams in the United States and United Kingdom to support pharmaceutical partners across more than 10 active drug development programs. Additionally, Orakl is negotiating agreements with over 15 cancer centers across Europe, North America, and Asia to expand its patient-derived biological datasets.
Orakl also intends to extend its technology into earlier-stage drug discovery, identifying potential therapeutic targets and combination treatments through experimental screening.
CEO and Co-Founder Dr. Fanny Jaulin emphasized the importance of predicting patient responses before clinical testing, positioning the platform as a tool for improving oncology drug development decisions.
Click here for the original news story.
